free bet
Samajwadi Party chief Akhilesh Yadav on Wednesday questioned the Uttar Pradesh government's preparedness for the upcoming Mahakumbh and accused it of mismanagement. In a social media post, the opposition leader flagged several issues regarding security arrangements, local concerns and overall administration in Prayagraj, urging the government to take immediate corrective action. ''This is the truth of preparations for 'Prayagraj Mahakumbh 2025' under the BJP government! At least the work of the police department should have been completed long ago because the management of the security circle does not wait for the last day,'' he said on X. The former chief minister of the state also drew attention to the alleged delay in addressing the needs of local residents and the fair area, stating that people in Prayagraj were questioning the government's priorities. ''The aggrieved people of Prayagraj are asking that the BJP government was very prompt in removing the statue of 'Mahadani' Emperor Harshvardhan, but why is the same speed not being shown for administrative management?'' Yadav highlighted complaints about the ''neglect'' of local issues, such as transportation and movement around the Mahakumbh area. ''Alternative arrangements should also be made to address the concerns of the residents of Prayagraj about movement and transportation in case of an emergency,'' he added. While expressing his party's support for the successful conduct of the Mahakumbh, Yadav emphasised that the local administration must act swiftly to address these gaps. ''We want the Mahakumbh to go on and Prayagraj to also remain dynamic.'' The SP president said his party is ready to assist the government as the ''BJP people would be ''busy earning money or in election planning''. ''If the government-administration has failed in the preparations for the Mahakumbh, then we propose to send our true and dedicated workers to help because the BJP people would be busy earning money or in election planning,'' he said in a dig at the ruling party. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)Jimmy Carter: A brief bio
A closer look at Ebbsfleet ahead of Boxing Day clash with Blues
Sabres get power-play goals from Zucker and Thompson in 4-2 win over the BluesWAITROSE has finally revealed who stole the dessert in its star-studded "whodunnit"-style Christmas advert. The upmarket retailer has released the final instalment in its two-part series centring around a mystery theft of a festive pudding. The clip sees the ensemble cast from the first advert returning, including Matthew Macfadyen of "Succession", comedian Joe Wilkinson from "Afterlife" and Rakhee Thakrar of "Sex Education". Sian Clifford from "Fleabag", Dustin Demri-Burns of "Slow Horses" and Eryl Maynard of "Agatha Christie’s Miss Marple" are also back. In the first part, the star-studded cast were left stunned after finding out a Waitrose desert had gone missing. The ad ends with self-appointed detective of the crime scene revealing that he had solved the mystery. The second one-minute clips picks up right where the first left off, with Macfayden working to establish a motive, switching back to moments on Christmas Day when the guilty party could have gotten their hands on the dessert. We then see the detective working out how someone could pull off such a delicious crime before revealing that Steve (Dustin Demri-Burns) hid the dessert in the gingerbread house under everyone's noses. He is then caught in the act in the family garden shed enjoying the first bite. Once unveiled, the film ends with the whole family digging into the delicious dessert. The first advert has amassed over 150million views across social, TV and digital channels, with viewers flocking to social media to guess who the culprit was. If you haven't seen the first part of the advert, you can watch it below. A poll by Waitrose found that Fig the Cat was the top suspect, with Steve - the real villain - the least suspected. Nathan Ansell, customer director at Waitrose, said: "The last few weeks have been filled with suspicion, guessing and alibis. "I can’t wait for everyone to find out who did it." While Dustin Demri-Burns, who plays food lover Steve said: "I can fully empathise with Steve and his pud-thieving ways. "The pressure of making Christmas wonderful can get to us all - sometimes we just want to eat our pudding in the shed and that’s ok." The ad, which was created by advertising agency Saatchi & Saatchi, will air tonight during Channel 4's Great British Bake Off and ITV's I’m a Celebrity Get Me Out of Here. For viewers wanting a slice of the action, The No.1 Red Velvet Dessert at the heart of the mystery will be available in Waitrose stores from December 19. But if you can't wait until then, it is available preorder now through the supermarket's website for £20. Consumer reporter Sam Walker reveals how you can save money on your Christmas shopping. Limit the amount of presents - buying presents for all your family and friends can cost a bomb. Instead, why not organise a Secret Santa between your inner circles so you're not having to buy multiple presents. Plan ahead - if you've got the stamina and budget, it's worth buying your Christmas presents for the following year in the January sales. Make sure you shop around for the best deals by using price comparison sites so you're not forking out more than you should though. Buy in Boxing Day sales - some retailers start their main Christmas sales early so you can actually snap up a bargain before December 25. Delivery may cost you a bit more, but it can be worth it if the savings are decent. Shop via outlet stores - you can save loads of money shopping via outlet stores like Amazon Warehouse or Office Offcuts. They work by selling returned or slightly damaged products at a discounted rate, but usually any wear and tear is minor. John Lewis' highly anticipated Christmas advert - called The Gifting Hour - follows a woman's last-minute dash to find a gift for her sister. Sainsbury's has unveiled its festive ad for 2024, featuring iconic Roald Dahl character the BFG. Meanwhile, Morrisons' Christmas ad has singing oven gloves taking centre stage. German discounter Aldi has teased a "super cute" ad, although shoppers have been left asking after Kevin the Carrot. The Debenhams campaign features an all-star cast - Elizabeth Hurley, Leomie Anderson, Ellie Taylor , and Hannah Cooper-Dommett - as they embrace the ease of online shopping. And the Argos Christmas ad stars the retailers' much-loved mascots, Connie the doll and Trevor the dinosaur. Retailers aren't just releasing Christmas ads this year either - some are shutting up shop for two days over the festive period. Home Bargains, Aldi and John Lewis and Waitrose have all said they will shut stores on December 25 and 26 to give staff time off. They've been joined by Poundland, The Range and Wilko and Homebase. Do you have a money problem that needs sorting? Get in touch by emailing money-sm@news.co.uk . Plus, you can join our Sun Money Chats and Tips Facebook group to share your tips and stories
DEMESNE RESOURCES LTD. ANNOUNCES CLOSING OF A THIRD TRANCHE OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT FINANCING
Making J&K TB-FreeCATL Launches the Bedrock Chassis That Withstands 120 km/h Impact Without Catching Fire or Exploding
Galaxy holds on to claim 6th MLS CupO'Connor scores 17 as George Mason knocks off Tulane 76-6470 Gifts under $25 on Amazon that are legitimately amazing
Shoppers ‘fall in love’ with Dollar Tree’s viral beauty item – it’s identical to Sephora but 94% cheaper
Transforming Creativity with the AI Spicy Story Generator
Thomas Sorber, Georgetown roll past Coppin State
Solid Tumor Testing Market to Grow at 5.9% CAGR, Projected to Hit USD 36.48 Billion by 2028 11-26-2024 09:40 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Data Bridge Market Research (DBMR) / PR Agency: Data Bridge Market Research (DBMR) The Solid Tumor Testing Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends. This comprehensive report provides key insights into the Solid Tumor Testing market, exploring critical market segmentation and definitions. It highlights the essential components driving growth, offering a clear picture of the industry's trajectory. Utilizing SWOT and PESTEL analyses, the report evaluates the market's strengths, weaknesses, opportunities, and threats, while also considering political, economic, social, technological, environmental, and legal factors that impact the market landscape. The study offers valuable insights into the competitive landscape, highlighting recent developments and geographical distribution across key regions. Expert competitor analysis provides a detailed understanding of market dynamics, offering strategic guidance for businesses and investors. With robust analysis and future projections, this report serves as a vital resource for stakeholders looking to capitalize on emerging opportunities and navigate challenges in the Solid Tumor Testing market. What is the projected market size & growth rate of the Solid Tumor Testing Market? Market Analysis and Insights : Global Solid Tumor Testing Market The solid tumor testing market is expected to witness market growth at a rate of 5.90% in the forecast period of 2021 to 2028, and is estimated to reach the value of USD 36,481.64 million by 2028. Data Bridge Market Research report on solid tumor testing market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The rapid advancements in the healthcare sector globally is escalating the growth of solid tumor testing market. Solid tumor testing refers to a procedure that is utilized for evaluating primary tumor and determining extent/location of any metastases. This type of testing allows effective treatment options to be considered in order to avoid the spread of cancerous cells. The rise in the number of people suffering from cancer across the globe acts as one of the major factors driving the growth of solid tumor testing market. The high utilization of spatial techniques for cancer research and diagnosis, and introduction of novel technologies for minimizing errors accelerate the market growth. The increase in number of establishment of various market players dealing in these technologies, and development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment further influence the market. Additionally, increase in investments, grants and funds, rise in population, surge in healthcare expenditure and rise in funding support by various organizations positively affects the solid tumor testing market. Furthermore, rise in demand for personalized medicine extend profitable opportunity to the market players in the forecast period of 2021 to 2028. On the other hand, difficulties with approval procedure are expected to obstruct the market growth. The presence of stringent regulations is projected to challenge the solid tumor testing market in the forecast period of 2021-2028. This solid tumor testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on solid tumor testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. Browse Detailed TOC, Tables and Figures with Charts which is spread across 350 Pages that provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector. This research report is the result of an extensive primary and secondary research effort into the Solid Tumor Testing market. It provides a thorough overview of the market's current and future objectives, along with a competitive analysis of the industry, broken down by application, type and regional trends. It also provides a dashboard overview of the past and present performance of leading companies. A variety of methodologies and analyses are used in the research to ensure accurate and comprehensive information about the Solid Tumor Testing Market. Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-solid-tumor-testing-market Which are the driving factors of the Solid Tumor Testing market? The driving factors of the Solid Tumor Testing market include technological advancements that enhance product efficiency and user experience, increasing consumer demand driven by changing lifestyle preferences, and favorable government regulations and policies that support market growth. Additionally, rising investment in research and development and the expanding application scope of Solid Tumor Testing across various industries further propel market expansion. Solid Tumor Testing Market - Competitive and Segmentation Analysis: Global Solid Tumor Testing Market, By Type (Conventional Testing, Non-Conventional Testing), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), Application (Clinical, Research), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2031 How do you determine the list of the key players included in the report? With the aim of clearly revealing the competitive situation of the industry, we concretely analyze not only the leading enterprises that have a voice on a global scale, but also the regional small and medium-sized companies that play key roles and have plenty of potential growth. Which are the top companies operating in the Solid Tumor Testing market? The major players covered in the solid tumor testing market report are BiovewInc, Aviva Biosciences, Laboratory Corporation of American Holdings (LabCorp), A&G Pharmaceutical, AffymetrixInc, Precision Therapeutics, ThermoFisher Scientific, Siemens, Menarini Silicon Biosystems, Myriad Genetics, Qiagen, Roche, Diadx, EONE- Diagnostics, Genome center, Exosome Sciences, iCellate Medical, Inivata, IV Diagnostics, LCM Genec, Celsee Diagnostics, Gen-Probe Inc, Digene, Quest Diagnostic Inc, and Cancer Genetics Inc, among other domestic and global players. Short Description About Solid Tumor Testing Market: The Global Solid Tumor Testing market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon. North America, especially The United States, will still play an important role which can not be ignored. Any changes from United States might affect the development trend of Solid Tumor Testing. The market in North America is expected to grow considerably during the forecast period. The high adoption of advanced technology and the presence of large players in this region are likely to create ample growth opportunities for the market. Europe also play important roles in global market, with a magnificent growth in CAGR During the Forecast period 2024-2031. Solid Tumor Testing Market size is projected to reach Multimillion USD by 2031, In comparison to 2024, at unexpected CAGR during 2024-2031. Despite the presence of intense competition, due to the global recovery trend is clear, investors are still optimistic about this area, and it will still be more new investments entering the field in the future. This report focuses on the Solid Tumor Testing in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Get a Sample Copy of the Solid Tumor Testing Report 2024 What are your main data sources? Both Primary and Secondary data sources are being used while compiling the report. Primary sources include extensive interviews of key opinion leaders and industry experts (such as experienced front-line staff, directors, CEOs, and marketing executives), downstream distributors, as well as end-users. Secondary sources include the research of the annual and financial reports of the top companies, public files, new journals, etc. We also cooperate with some third-party databases. Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2031) of the following regions are covered in Chapters What are the key regions in the global Solid Tumor Testing market? North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Turkey etc.) Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam) South America (Brazil, Argentina, Columbia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) This Solid Tumor Testing Market Research/Analysis Report Contains Answers to your following Questions What are the global trends in the Solid Tumor Testing market? Would the market witness an increase or decline in the demand in the coming years? What is the estimated demand for different types of products in Solid Tumor Testing? What are the upcoming industry applications and trends for Solid Tumor Testing market? What Are Projections of Global Solid Tumor Testing Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about Import and Export? Where will the strategic developments take the industry in the mid to long-term? What are the factors contributing to the final price of Solid Tumor Testing? What are the raw materials used for Solid Tumor Testing manufacturing? How big is the opportunity for the Solid Tumor Testing market? How will the increasing adoption of Solid Tumor Testing for mining impact the growth rate of the overall market? How much is the global Solid Tumor Testing market worth? What was the value of the market In 2020? Who are the major players operating in the Solid Tumor Testing market? Which companies are the front runners? Which are the recent industry trends that can be implemented to generate additional revenue streams? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Solid Tumor Testing Industry? Customization of the Report Can I modify the scope of the report and customize it to suit my requirements? Yes. Customized requirements of multi-dimensional, deep-level and high-quality can help our customers precisely grasp market opportunities, effortlessly confront market challenges, properly formulate market strategies and act promptly, thus to win them sufficient time and space for market competition. Detailed TOC of Global Solid Tumor Testing Market Insights and Forecast to 2031 Introduction Market Segmentation Executive Summary Premium Insights Market Overview Solid Tumor Testing Market By Type Solid Tumor Testing Market By Function Solid Tumor Testing Market By Material Solid Tumor Testing Market By End User Solid Tumor Testing Market By Region Solid Tumor Testing Market: Company Landscape SWOT Analysis Company Profiles Continued... https://futureresearchinsight1500.blogspot.com/2024/11/weatherization-services-market-size.html https://futureresearchinsight1500.blogspot.com/2024/11/static-random-access-memory-sram-market.html https://futureresearchinsight1500.blogspot.com/2024/11/prepared-meat-and-seafood-equipment.html Data Bridge Market Research: Today's trends are a great way to predict future events! Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience. Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC: +653 1251 975 Email:- corporatesales@databridgemarketresearch.com This release was published on openPR.Gabriel mimics Gyokeres in cheeky goal celebration in Arsenal win over Sporting in Champions LeagueJimmy Carter: Many evolutions for a centenarian ‘citizen of the world’
CHARLESTON, Ill. (AP) — Zion Fruster had 15 points in Eastern Illinois' 99-55 victory over Division-III Blackburn on Saturday night. Fruster shot 6 of 11 from the field, including 1 for 3 from 3-point range, and went 2 for 3 from the free-throw line for the Panthers (4-8). Obadiah Curtis added 15 points while going 7 of 9 from the field while they also had five steals. Kooper Jacobi went 6 of 9 from the field to finish with 13 points. Odis Grissom led the Beavers in scoring, finishing with 19 points. Blackburn also got seven points and five assists from Darius Duff. Caleb Schaab had seven points and two steals. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Before Payton Steele was diagnosed with Hodgkin’s Lymphoma, she never imagined she would go through menopause when she was barely out of her teen years. Two months into chemotherapy , Steele’s period disappeared, and she began to develop hot flashes . Then came the hair loss . Although she finished her treatments in September, the early menopause symptoms continue to affect her daily life, Steele tells SELF, but above all, her self-confidence. “It's definitely not something I thought I would have to deal with at 20,” she says. “And knowing that I might not be able to have kids in the future is just really rough and makes me really sad.” This is the reality for a lot of younger people who’ve been diagnosed with cancer. Most folks with a period transition into menopause sometime between the ages 45 and 55. At that point, their ovaries start to produce less of the hormones estrogen and progesterone. But medical menopause—when your ovaries are removed, shut down, or stop working as a result of chemotherapy, radiation to the pelvis, medications, or surgery—can mean this process begins well before age 45. It’s often referred to as early or premature menopause (but we’ll stick with “early” for simplicity’s sake). Symptoms like hot flashes, sleep problems, mood changes, and vaginal dryness can hit pretty hard following cancer treatment. That’s because your ovaries lose their function right away, as opposed to gradually as you age. But the likelihood your cancer treatment puts you into early menopause depends on several factors, including the age you were diagnosed and the dose and type of therapy you receive. It’s also not always a permanent situation; some people’s ovaries can start back up again after a little break. Whether your early menopause is temporary or lifelong, the situation is still pretty crappy. But there are a number of ways you can find relief from your symptoms, and some people may even be able to prevent issues like infertility. Here’s everything to know about how cancer treatment can affect your risk of early menopause. 3 cancer treatments that can cause early menopause Sometimes the best thing you can do to get rid of your cancer and lower the chances it comes back is to surgically remove both of your ovaries (known as an oophorectomy). This is especially true for ovarian cancer, or any other that can spread into the ovaries (like colorectal cancer, for example). This type of procedure is “an automatic ticket into menopause,” Shanthi Sivendran, MD , a medical oncologist and senior vice president of cancer treatment support with the American Cancer Society, tells SELF. If your ovaries are removed, your period won’t come back and your hormone levels will drop quickly, which means menopause starts right away and your symptoms may be really intense. In some cases, though, your doctor may try to leave one or part of an ovary, which can help prevent early menopause. You may also need to remove your ovaries if you carry a genetic mutation (specifically the BRCA1 or BRCA2 genes) that increases your risk of certain diseases, Dr. Sivendran says. One study found that women who underwent this surgery had a 96% and 53% reduction in their risk of ovarian and breast cancer, respectively. These specific cancers are estrogen-dependent, meaning they rely on this hormone to grow; so removing the organ that produces it essentially starves and prevents them from developing in the first place. If your surgeon removes your uterus (but keeps your ovaries) as part of your cancer treatment, you may not go into early menopause right away, but you might develop it a year or two earlier than normal. All types of chemotherapy have the potential to affect your ovaries, but certain types that use drugs like Cytoxan (which can treat a bunch of cancers, including Hodgkin’s lymphoma, multiple myeloma, and breast cancer) are known for causing early menopause. This is because chemo destroys rapidly dividing cells in the body, which includes cancer cells and the normal cells in your ovaries. Some data indicate that a lot of people who initially go into early menopause get their periods again about two years after they finish chemo. But again, this depends on what kind of drug you receive, the cancer you have, and your age. For example, one type of chemo that people with leukemia or lymphomas may get before a stem-cell transplant is known for inducing early menopause in about 80% of people. Generally, though, the older you are, the higher your risk of developing early menopause and the harder it may be for your ovaries to recover. This is one of those cancer treatments that’s very much dose dependent, meaning the more radiation you get, the greater your chances of going into early menopause. If you get radiation near your ovaries, it’s pretty much guaranteed that you’ll be kicked into menopause territory. Meanwhile, any radiation done in your pelvis region, say to treat colorectal or cervical cancers, has been shown to cause early menopause in about 94% of women. “Even though we do our best to try to minimize other organs from being impacted, there may still be some radiation exposure to the ovaries,” Dr. Sivendran says. How do I know if I’m in early menopause? There’s no exact science to determine whether you’ve hit menopause, but you generally know you’re in it when you haven’t had your period for 12 consecutive months and you’ve been experiencing symptoms like hot flashes, night sweats, and trouble sleeping. However, it can be especially difficult to tell you’re in early menopause after cancer treatment. First, menopause symptoms like fatigue and sexual dysfunction (including low desire, pain, or anything else that prevents you from enjoying sex) can be confused with those related to cancer or the treatment itself. And second, the telltale 12-month-no-period criteria doesn’t always apply to cancer patients because your ovaries may return to regular programming several months to years after treatment, Dr. Sivendran says. Staying in touch with your medical team as you navigate post-treatment symptoms will give you a better idea of whether your menopause is here to stay, and guide you to any therapies you might want or need to feel better. What does treatment for cancer-related early menopause look like? Your treatment options are similar to those for people undergoing natural menopause, which may be a low-dose antidepressant to treat hot flashes , for example. But there’s one treatment that some people with early menopause should avoid: Systemic hormone therapy , which is essentially hormones delivered via a pill, patch, foam, gel or spray that affects the entire body, Dr. Sivdenran says. These meds are basically estrogen with or without progesterone. So for people with breast, ovarian, or uterine cancers that rely on one or both of these hormones to grow, this specific therapy may not be safe as it can increase the chances your cancer comes back. Dr. Sivdenran says it’s a good idea to talk with your doctor so you can discuss your personal risk-benefit ratio and ensure that your most concerning symptoms are actually being addressed. Is early menopause after cancer permanent? As we mentioned, there are certain scenarios where your ovaries may get back into the swing of things after cancer treatment, but for some people, their early menopause may be permanent. Meghan Karuturi, MD , a breast medical oncologist with the University of Texas MD Anderson Cancer Center, says that age is one of the strongest predictors of this. The younger you are, the more likely menopause isn’t permanent, but it’s “just a measure of time,” she tells SELF, meaning it can take months to years for your ovarian function to return. In a 2016 study , about 70% of the women aged 20–35 who lost their period—an indicator of early menopause—gained it back after their cancer treatment, which included radiation and/or chemo. Most of them got it back within two years, and those on the older side were more likely to have an irregular cycle. (And again, if you’ve had surgical removal of the ovaries or uterus, it won’t ever come back.) There are circumstances where you can take some steps prior to cancer treatment to reduce your chances of early menopause. For example, if you still can and want to have children after your cancer treatment, you can take luteinizing hormone-releasing hormone (LHRH) agonists that will temporarily stop your ovaries from working. These meds can not only protect your ovaries from damage that might lead to infertility, but they can also make other cancer drugs more effective and even reduce the risk your cancer comes back. You’ll experience typical menopause symptoms when you’re taking these meds, but they should go away when you stop. How quickly that happens is specific to you and your circumstances, though. If you want to take extra fertility precautions, you can also consider harvesting your eggs before you start your treatment. They can be frozen, or combined with sperm to create embryos first and then frozen, so the eggs can be used in the future to try for a pregnancy. These procedures can be pretty pricey (about $10,000 or more each time you go through a cycle to collect eggs) and not all insurance companies cover it. So be sure to discuss this with your medical team as early as possible to see if this is an option for you and to avoid running into issues that might interfere with your family planning goals. Does early menopause increase my risks for other health issues? Yes, it could, but it depends on a bunch of factors. Menopause in general, because of low estrogen levels, can lead to the bone thinning disease osteoporosis, which makes fractures more likely. These hormone changes can also increase your risk of heart disease by affecting things like blood pressure and cholesterol levels. And lots of people can also experience menopause-related brain fog and problems with memory, decision making, and concentration, Dr. Karuturi says. In practice, that means you might have to get your bone density checked earlier than usual (this typically happens around age 65, but can occur beginning at age 50 if you have certain risk factors like this one), Dr. Karuturi says. It’s also a good idea to chat with your doctor about other preventive measures you can take to lower your chances of these issues, she adds, like exercising regularly and taking certain vitamins. Above all, early menopause can really put your mental health through the wringer. “It's difficult to feel like you’re going through [menopause] when you didn't anticipate going through it early..... That can impact your daily functioning if you're not getting enough sleep; your work; how you view yourself,” Dr. Sivendran says. “All of these things are just really important struggles that young women who go through early menopause deal with.” Although early menopause after cancer can feel devastating, there are steps you can take before and after treatment to ease any symptoms or problems. Ask your medical team if your hospital system offers resources to connect patients locally or even nationwide or look for virtual support groups on social media that meet your needs. “It’s just important for you to know that this isn’t something you have to experience in isolation,” Dr. Karuturi says. This made a world of difference for Steele, who was able to find someone like her who she could rely on for emotional support. “I have a friend who lives super close to me. We had the same cancer, same stage, and we’re the same age, too, which is really cool.” Related: 6 Ways to Deal With Night Sweats During Menopause How to Make New Friends as an Adult When You Have a Chronic Illness What to Know About Drinking During Menopause Get more of SELF’s great service journalism delivered right to your inbox—for free .
What's Going On With FREYR Battery Stock On Tuesday?
Vikings place linebacker Ivan Pace Jr. on injured reserve, sign former first-round pick Jamin DavisPHILADELPHIA (AP) — Cole Hargrove's 17 points helped Drexel defeat Pennsylvania 60-47 on Saturday. Hargrove also contributed 13 rebounds and three blocks for the Dragons (6-4). Kobe Magee scored 12 points while shooting 4 for 12 (0 for 3 from 3-point range) and 4 of 4 from the free-throw line and added five rebounds. Yame Butler had 10 points and shot 4 of 7 from the field and 2 of 4 from the free-throw line. Nick Spinoso led the Quakers (3-6) in scoring, finishing with 21 points, seven rebounds and two steals. Ethan Roberts added 11 points for Pennsylvania. Sam Brown had eight points. Drexel got a team-high six points across the first half from Hargrove, but it was only enough to head to the locker room with the score tied at the half 30-30. Drexel took a 10-point lead in the second half thanks to a 16-2 scoring run. Hargrove led their club in second-half scoring with 11 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Chaikin scores 20 as Lafayette takes down Mercyhurst 77-73